MK-1454/Keytruda Combination Shows Promise in Solid Tumor and Lymphoma Patients
News
A combination of the investigational agent MK-1454 and Keytruda (pembrolizumab) induced robust and durable responses in solid tumor and lymphoma patients in a Phase 1 trial, Merck (known as MSD outside the ... Read more